Clinical and pharmacokinetic study of gemcitabine (GEM) - oxaliplatin (OXA) association in metastatic or locally advanced pancreatic adenocarcinoma.

被引：0
|
作者：
Airoldi, M
Cattel, L
Passera, R
Micari, C
Ferrarato, E
Zanon, C
机构：
[1] Osped San Giovanni Ant Sede, Turin, Italy
[2] Univ Turin, Fac Farm, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2059
引用
收藏
页码：141S / 141S
页数：1
相关论文
共 50 条
  • [1] ASSOCIATION OF GEMCITABINE (GEM) AND OXALIPLATIN (OXA) IN METASTATIC OR LOCALLY ADVANCED PANCREATIC ADENO-CARCINOMA: A CLINICAL AND PHARMACOKINETIC (PK) STUDY
    Airoldi, M.
    Cattel, L.
    Passera, R.
    Micari, C.
    Nigro, A.
    Milla, P.
    ANNALS OF ONCOLOGY, 2004, 15 : 68 - 68
  • [2] Alternative scheduling of Gemcitabine (GEM) - Oxaliplatin (OXA) association in metastatic (MTS) or locally advanced (LA) pancreatic adenocarcinoma: a clinical and pharmacokinetic (pk) evaluation
    Airoldi, Mario
    Cattel, Luigi
    Pedani, Fulvia
    Micari, Caterina
    Nigro, Anna
    Branciforte, Lino
    Zanon, Claudio
    Milla, Paola
    ANNALS OF ONCOLOGY, 2004, 15 : 241 - 241
  • [3] Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma - Clinical and pharmacokinetic data
    Airoldi, M
    Cattel, L
    Passera, R
    Pedani, F
    Milla, P
    Zanon, C
    PANCREAS, 2006, 32 (01) : 44 - 50
  • [4] Gemcitabine and oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer
    All, M.
    Carillio, G.
    Mazzola, A.
    Bagnato, S.
    Di Leo, M. G.
    Fallica, G.
    Anna, Aiello R.
    Chiarenza, M.
    Caruso, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI52 - XI52
  • [5] NCCTG phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma.
    Kim, G. P.
    Oberg, A.
    Kabat, B.
    Sing, A.
    Hedrick, E.
    Campbell, D.
    Alberts, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 206S - 206S
  • [6] Phase II study of gemcitabine and cisplatin in locally advanced or metastatic gallbladder or bile duct adenocarcinoma.
    Servienti, PJ
    Carraro, S
    Bruno, MF
    Odena, MSC
    Felci, N
    Montiel, M
    Roca, E
    Araujo, CE
    ANNALS OF ONCOLOGY, 2000, 11 : 71 - 71
  • [7] A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Schultheis, Beate
    Strumberg, Dirk
    Kuhlmann, Jan
    Wolf, Martin
    Link, Karin
    Seufferlein, Thomas
    Kaufmann, Joerg
    Gebhardt, Frank
    Bruyniks, Nico
    Pelzer, Uwe
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [8] A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
    Macarulla, Teresa
    Tabernero, Josep
    Palmer, Daniel H.
    Sharma, Sunil
    Yu, Kenneth H.
    Sellami, Dalila B.
    Zhou, Jocelyn
    Yi, Wu
    Boss, Hildegard
    Kwak, Eunice L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] A pilot study of gemcitabine (g), oxaliplatin (o), cetuximab (c) for locally advanced or metastatic pancreatic cancer
    Merchan, J. R.
    Venkatraman, A.
    Macintyre, J.
    Ciombor, K.
    Levi, J.
    Ribeiro, A.
    Sleeman, D.
    Aurea, F.
    Vulfovich, M.
    Rocha-Lima, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Neoadjuvant FOLFIRINOX and/or gemcitabine/nabpaclitaxel for advanced pancreatic adenocarcinoma.
    Turner, Keli
    Narayanan, Sumana
    Attwood, Kristopher
    Hochwald, Steven N.
    Iyer, Renuka V.
    Kukar, Moshim
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345